Section of Urology, University of Chicago, Chicago, Illinois.
Department of Urology, University of Washington, Seattle, Washington.
Urol Pract. 2023 Nov;10(6):656-663. doi: 10.1097/UPJ.0000000000000457. Epub 2023 Sep 26.
Patients with mental health disorders are at risk for receiving inequitable cancer treatment, likely resulting from various structural, social, and health-related factors. This study aims to assess the relationship between mental health disorders and the use of definitive treatment in a population-based cohort of those with localized, clinically significant prostate cancer.
We conducted a cohort study analysis in SEER (Surveillance, Epidemiology, and End Results)-Medicare (2004-2015). History of a mental health disorder was defined as presence of specific ICD (International Classification of Diseases)-9 or ICD-10 diagnostic codes in the 2 years preceding cancer diagnosis. Descriptive statistics were performed using Wilcoxon rank-sum and χ testing. Multivariable logistic regression was used to evaluate the relationship between mental health disorders and definitive treatment utilization (defined as surgery or radiation).
Of 101,042 individuals with prostate cancer, 7,945 (7.8%) had a diagnosis of a mental health disorder. They were more likely to be unpartnered, have a lower socioeconomic status, and less likely to receive definitive treatment (61.8% vs 68.2%, < .001). Definitive treatment rates were >66%, 62.8%, 60.3%, 58.2%, 54.3%, and 48.1% for post-traumatic stress disorder, depressive disorder, bipolar disorder, anxiety disorder, substance abuse disorder, and schizophrenia, respectively. After adjusting for age, race and ethnicity, marital status and socioeconomic status, history of a mental health disorder was associated with decreased odds of receiving definitive treatment (OR 0.74, 95% CI 0.66-0.83).
Individuals with mental health disorders and prostate cancer represent a vulnerable population; careful attention to clinical and social needs is required to support appropriate use of beneficial treatments.
患有精神健康障碍的患者在接受癌症治疗方面可能存在不平等现象,这可能是由于各种结构性、社会性和与健康相关的因素造成的。本研究旨在评估精神健康障碍与局部、临床显著前列腺癌患者群体中确定性治疗使用之间的关系。
我们在 SEER(监测、流行病学和最终结果)-医疗保险(2004-2015 年)中进行了队列研究分析。精神健康障碍史的定义为癌症诊断前 2 年内存在特定的 ICD(国际疾病分类)-9 或 ICD-10 诊断代码。使用 Wilcoxon 秩和和 χ 检验进行描述性统计。多变量逻辑回归用于评估精神健康障碍与确定性治疗利用之间的关系(定义为手术或放疗)。
在 101042 名患有前列腺癌的个体中,有 7945 名(7.8%)被诊断出患有精神健康障碍。他们更有可能未婚、社会经济地位较低,并且不太可能接受确定性治疗(61.8%比 68.2%,<0.001)。确定性治疗率分别为创伤后应激障碍、抑郁障碍、双相情感障碍、焦虑障碍、物质使用障碍和精神分裂症的>66%、62.8%、60.3%、58.2%、54.3%和 48.1%。调整年龄、种族和民族、婚姻状况和社会经济地位后,精神健康障碍史与接受确定性治疗的可能性降低相关(OR 0.74,95%CI 0.66-0.83)。
患有精神健康障碍和前列腺癌的个体是一个弱势群体;需要仔细关注临床和社会需求,以支持适当利用有益的治疗方法。